Even considering that we obtained data from a limited number of subjects, the increase in alpha-CGRP found here was clear even in the presence of drugs such as corticosteroids or analgesics, which could theoretically diminish CGRP release, and supports a role for this neuropeptide in the headache manifestations of COVID-19 and, together with the recently described specific increase in beta-CGRP serum levels in COVID-19 patients with diarrhea (18), suggests that CGRP could be one of the molecules released in the cytokine storm induced by the COVID-19 infection. The gene discussed is CALCB; the disease is COVID-19.